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1. Introduction 
Coronary artery disease (CAD) is a leading cause of mortality and morbidity in most 
developed countries [1]. Many studies have found gender-related differences in the 
presentations, prevalence, and clinical outcomes of CAD [2-4]. CAD first presents itself in 
women approximately 10 years later than in men, most commonly after menopause [5].  The 
worldwide INTERHEART study, a large study of more than 52000 individuals with MI, first 
demonstrated that this approximate 8 to 10 year difference in age at onset holds widely 
around the world, across various socioeconomic, climatic, and cultural environments. 
Although coronary artery disease in general is manifestated earlier in less developed 
countries, the age gap in time of onset between men and women is universal (Table 1) [6]. 
Region Median age, women Median age, men
Western Europe 68 (59-76) 61 (53-70)
Central and eastern Europe 68 (59-74) 59 (50-68)
North America 64 (52-75) 58 (49-68)
South America and Mexico 65 (56-73) 59 (50-68)
Australia and New Zealand 66 (59-74) 58 (50-67)
Middle East 57 (50-65) 50 (44-57)
Africa 56 (49-65) 52 (46-61)
South Asia 60 (50-66) 52 (45-60)
China and Hong Kong 67 (62-72) 60 (50-68)
Southeast Asia and Japan 63 (56-68) 55 (47-64)  
Table 1. Comparison of age at first myocardial infarction among women and men across 
geographic regions: Effect of potentially modifiable risk factors associated with myocardial 
infarction in 52 countries (the INTERHEART study): Case-control study [6].  
Compared to women, men present with ST-segment elevation myocardial infarction (MI) 
more often and have a higher prevalence of CAD adjusted for age [7,8]. However, younger 
women experience more adverse outcomes after MI and coronary artery bypass grafting 
surgery than men [9]. A greater proportion of women than men with MI die of sudden 
cardiac arrest before reaching hospital [3,10]. Previous reports have shown a 20% reduction 
in total mortality among patients randomized to exercise-based cardiac rehabilitation 
compared with controls receiving usual care [11]. The outcome was however similar 
between men and women, although only 20% of all participants were women in many 
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reports. Women are less likely than men to participate in cardiac rehabilitation after acute 
MI [11].  
The prevalence of microvascular angina is higher in women than men. Takotsubo 
cardiomyopathy is more prevalent in women than in men [12]. These findings indicate that 
gender difference may have an important influence on cardiovascular physiology and 
pathology [13,14]. 
In many developing countries, a large budget is expended for the treatment of CAD, and it 
is necessary to minimize the influence of risk factors. The burden of CAD on women and the 
global economy will continue to increase [5]. In addition to population-based and 
macroeconomic interventions, interventions in individual patients are key to reducing the 
incidence of CAD globally [15]. Prevention of CAD is paramount to the health of every 
woman and every nation. 
There have been numerous clinical trials that have a bearing on CAD prevention in women 
[16]. Women and men differ in their genetic complement by a single chromosome out of the 
46 that are present in the human species. However, this single chromosomal difference 
affects both the expression of disease and the psychosocial and behavioral characteristics 
and work environments of individuals, which may reduce or increase the susceptibility to 
cardiovascular diseases. 
In future, novel drugs for tailor-made therapy of CAD based on gender differences may be 
developed. This review discusses gender differences in the features of ischemic heart disease 
and the possibilities of future developments in treatments. 
2. Clinical risk factors of coronary artery disease in women 
It is important to classify women as being at high, intermediate, or low risk for CAD. 
Classification may be based on clinical criteria and the Framingham global risk score [17]. A 
woman found to have coronary calcification or increased carotid intimal thickness may be at 
low risk for CAD on the basis of the Framingham risk score, but she may be actually at 
intermediate or high risk for a future CAD event. 
We should take several factors into consideration, including medical and lifestyle histories, 
Framingham risk score, family history of CAD, and other genetic conditions (e.g., familial 
hypercholesterolemia), since these affect the decisions about the aggressiveness of 
preventive therapy. Novel CAD risk factors (e.g., high-sensitivity C-reactive protein [18]) 
and novel screening technologies (e.g., coronary calcium scoring) should help guide 
preventive interventions. Further research is needed on the benefits, risks, and costs 
associated with such strategies. There are many unique opportunities for early detection of 
CAD in women; for example, in pregnancy, preeclampsia may be an early indicator of CAD 
risk [19,20]. In addition, maternal placental syndromes in combination with traditional 
cardiovascular risk factors, such as pre-pregnancy hypertension or diabetes mellitus, 
obesity, dyslipidemia, and metabolic syndrome, may be additive in defining CAD risk in 
women [19]. Future research should evaluate the potential for events or medical contact 
during unique phases in a woman’s life, such as adolescence, pregnancy, and menopause, to 
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identify women at high risk, and determine the effectiveness of preventive interventions 
during critical periods. 
The diagnosis of CAD in women presents challenges not observed in case of men. 
Differences in the epidemiology of CAD between men and women show that women are 
generally at a lower risk than their male counterparts until the seventh decade of life. For 
both asymptomatic and symptomatic women, the choice of initial test is guided by 
classification into low, intermediate, or high pretest risk categories. Asymptomatic 
intermediate-risk women have lower event rates. In symptomatic women, noninvasive 
diagnostic studies (exercise electrocardiography (ECG) and cardiac imaging studies) are 
recommended for those who are at an intermediate to high pretest likelihood of CAD [21]. 
Therapeutic decision-making is guided by the extent and severity of inducible ischemia. 
Thus, referral of low-likelihood women (for example, premenopausal women with less than 
one risk factor and non-anginal/atypical symptoms) will be associated with a high rate of 
false positives. 
Smoking is an important risk factor for vascular diseases. Vascular disease risk was most 
quickly reduced by cessation of smoking compared with other associated factors. The 
beneficial effect of quitting on the risk for death from CHD was realized within 5 years, 
whereas the risks for death from chronic obstructive pulmonary disease and lung cancer did 
not approach those of women who had never smoked until the age of 20 and 30 years, 
respectively [22]. It may never be too late for women to quit smoking in order to reduce the 
risk for vascular diseases.  
A blood pressure-lowering treatment provided similar protection against major 
cardiovascular events in men and women [23]. 
3. Features of coronary artery pathology in women 
Men have a greater burden of atheroma and eccentric atheroma in coronary arteries 
compared to women. A study reported that plaque rupture in patients with sudden 
coronary death was more frequent in men than in women [24]. 
Men have more severe structural and functional abnormalities in the epicardial coronary 
arteries than women. These factors may influence the higher incidence rates of CAD and ST-
segment MI (STEMI) in men compared to women. With regard to the lower cardiac event 
rate in female patients, several mechanisms have been proposed to explain the 
cardioprotective effect of sex hormones in women [13]. We show the effect of sex hormones 
in ischemic heart disease in table 2. 
Women had lower rates of obstructive CAD at angiography when evaluated for symptoms 
suggestive of myocardial ischemia [25]. Among angiographic CAD patients, atheroma 
volume in women is less than that in men, despite the presence of more cardiovascular risk 
factors in women. Women had slightly lower coronary vasodilator reserve even with 
normal coronary angiographic results [26]. Endothelial-independent microvascular 
dysfunction was an independent predictor of adverse outcomes in patients with mild CAD 
[27]. It has been suggested that the mechanism of myocardial ischemia in women may be 
localized to the microvascular coronary arteries and that abnormal microvascular function 
may have prognostic implications [28]. 
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PAI-1: plasminogen activator inhibitor-1, AT III: antithrombin III, ACE: angiotensinogen converting 
enzyme, VSMC: vascular smooth muscle cell. 
Table 2. Effect of estrogen on atherosclerosis.  
4. Takotsubo cardiomyopathy 
Takotsubo cardiomyopathy (or transient LV apical ballooning syndrome) is more prevalent 
in women than in men. Because the onset of this syndrome is often preceded by emotional 
or physical stress, catecholamine-mediated multivessel epicardial spasm, microvascular 
coronary spasm, or possible direct catecholamine-mediated myocyte injury have been 
advocated as possible pathophysiological mechanisms [12]. Electrocardiographic findings 
are like myocardial infarction. The left ventricular wall motion is akinetic from the middle to 
apex of the left ventricle on the left ventriculography and echocardiography [29]. The 
epicardial coronary artery stenosis is absent in the coronary angiography. Cardiac magnetic 
resonance can be useful for differentiating apical ballooning syndrome from an acute 
coronary event [12]. Late gadolinium enhancement in this setting represents a 
disproportionate expansion of extracellular matrix with increased collagen I deposition on 
immunohistochemical tissue staining [30]. 
5. Diagnosis and prognosis 
5.1 Electrocardiography 
Changes in ECG during exercise have been reported to be of diminished accuracy in women 
as a result of more frequent changes in resting ST-T wave, lower ECG voltage, and 
hormonal factors such as endogenous estrogen in premenopausal women and hormone 
replacement therapy in postmenopausal women [31-33]. In a meta-analysis of exercise ECG 
studies in women, sensitivity was 61% and specificity was 70%, compared to 72% and 77%, 
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respectively, in men [21]. From a cohort of symptomatic women who were referred for 
exercise treadmill testing followed by coronary angiography, significant coronary stenosis 
(more than 75%) was observed in 19%, 35%, and 89% of low-, moderate-, and high-risk 
women, respectively, based on Duke treadmill score risk categories [34]. 
Maximal exercise capacity and heart rate recovery measurements can aid in estimation of 
near- and long-term outcome in large cohorts of women [35]. Recent reports have noted that 
a simple measure such as heart rate recovery (at 1 or 2 min after exercise) have substantial 
prognostic value. 
Women engage less often in physical exercise programs, have lower functional capacity, and 
show a greater functional decline during their menopausal years. Because of their lower 
work capacity on exercise tests (on average 5–7 min) as a result of premature peripheral 
fatigue, it is difficult to provoke myocardial ischemia [36]. Women who exercise less than 5 
metabolic equivalents (METs) are at an increased risk for death [37]. Women expected to 
perform less than 5 METs may be better evaluated by pharmacological stress imaging. 
However, women who have inducible ischemia at low workloads (less than 5 METs) have a 
higher likelihood of obstructive CAD and may be referred for coronary angiography. 
The exercise ECG test has a high negative predictive value in women with a low pretest 
probability of CAD and a low-risk Duke treadmill score [21]. The diagnostic and prognostic 
accuracy of the exercise ECG stress test in symptomatic women with suspected CAD is 
increased by the inclusion of additional parameters in the interpretation of the ST-segment 
response to exercise. 
5.2 Echocardiography 
Stress echocardiography can provide information about the presence of left ventricular 
systolic or diastolic dysfunction, valvular heart disease, and the extent of infarction and 
stress-induced ischemia. Exercise echocardiography may be performed with a treadmill or 
by supine or upright bicycle exercise. Exercise stress echocardiography is a physiological 
investigation and the most widely available method for evaluation of CAD. However, 
exercise capacity is often impaired in aged or diabetic patients and the workload required to 
produce stress-induced myocardial ischemia might not be achieved by such patients. 
Stress echocardiography provides significantly higher specificity and accuracy than the 
standard exercise ECG testing in women [38]. 
Stress echocardiography has demonstrated good diagnostic accuracy for detecting or 
excluding significant CAD, with a mean sensitivity of 81%, specificity of 86%, and an overall 
accuracy of 84% [38-41]. There appears to be no significant effect of gender on the diagnostic 
accuracy of exercise echocardiography. 
A study of dobutamine stress echocardiography (DSE) revealed an overall sensitivity of 80% 
and specificity of 84% [39]. To exercise stress echocardiography, DSE appears to have 
similar diagnostic accuracy in detecting CAD in both women and men. 
Cardiac events occur less frequently in women than in men. This difference is compatible 
with the lower prevalence and lesser sensitivity of detection of CAD in women compared to 
men. No gender differences have been reported in the prognostic value of exercise stress 
echocardiography in a large population. 
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The low specificity of exercise ECG testing in women, especially in young and middle-aged 
women, may lead to a higher rate of unnecessary angiography and higher expense, 
particularly if stress imaging is not used before coronary angiography in a sequential testing 
strategy. 
Stress echocardiography with exercise or dobutamine is an effective and highly accurate 
noninvasive means of detecting ischemic heart disease and risk-stratifying symptomatic 
women with an intermediate to high pretest likelihood of CAD. Stress echocardiography 
provides incremental value over exercise ECG and clinical variables in women with 
suspected or known coronary heart disease. Stress echocardiography is recommended for 
symptomatic women with an intermediate or high pretest probability of CAD (women with 
suspected CAD must also have an abnormal resting ECG). Previous reports demonstrated 
that pharmacological stress echocardiography provides independent prognostic information 
in both men and women [42,43]. 
5.3 Myocardial perfusion 
Gated myocardial perfusion single-photon emission computed tomography (SPECT) is a 
nuclear-based technique that provides a combination of test elements that are used to 
diagnose and risk-stratify women. Myocardial perfusion imaging, however, has been 
reported to have technical limitations in women, including false-positive results due to 
breast attenuation and small left ventricular chamber size [44]. 
The accuracy of 201Tl SPECT imaging, for example, is reduced in patients with small hearts, 
and these patients are more likely to be women than men. When 201Tl is used as the 
radioisotope in women, false-positive test results may occur due to soft tissue attenuation 
(e.g., breast attenuation) in the anterior and anterolateral segments [44]. 
For women, the lower-energy isotope 201Tl has been largely supplanted by technetium-
based imaging agents that improve accuracy. In comparing the diagnostic accuracy of 201Tl 
with gated 99mTc-sestamibi SPECT in women, the sensitivity for detecting CAD was 80%, 
and test specificity improved dramatically from 67% for 201Tl to 92% for gated 99mTc-
sestamibi SPECT [45]. 
Pharmacological stress SPECT also merits consideration, given the higher incidence of 
decreased exercise capacity and advanced age for women, as discussed previously [44,46]. 
Vasodilator pharmacological stress perfusion imaging has been shown to be more accurate 
than exercise perfusion imaging in identification of CAD in both men and women with left 
bundle-branch block [46]. Adenosine 99mTc-sestamibi imaging was reported to have 91% 
sensitivity and 86% specificity for detecting significant coronary artery stenoses of more 
than 50% [47]. 
Myocardial perfusion imaging has powerful predictive value with regard to the 
development of subsequent cardiac death or MI or the need for coronary revascularization 
[48-50], regardless of sex [36]. Prognosis worsens commensurate with the number of 
vascular territories involved, with 3-year survival rates ranging from 99% for women 
without ischemia to 85% in women who had three-vessel ischemia [36]. 
In addition, pharmacological stress was recently shown to be effective in the risk 
stratification of diabetic women with suspected and known CAD. The CAD mortality for 
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non-diabetic women with a moderately abnormal scan was 2.8% compared with 4.1% in 
diabetic women [48]. 
6. Treatment 
Studies have shown that percutaneous coronary intervention (PCI) is a more effective 
reperfusion strategy for acute coronary syndrome than intravenous thrombolysis [51]. The 
advantage of primary PCI over thrombolytic therapy was greater for women than men [52]. 
Primary PCI reduced the risk of intracranial bleeding and improved survival in women [53]. 
Mortality from acute MI (AMI) was higher in women than in men, consistent with the 
results of most previous studies [52,54,55]. This poorer outcome in women was likely related 
to the facts that compared to men, women with AMI were older, underwent PCI less 
frequently, and had higher incidences of coronary risk factors, such as hyperlipidemia, 
diabetes mellitus, and hypertension. 
The use of a drug-eluting stent makes the outcome after PCI better than that after the use of 
a bare metal stent. There is no difference between men and women in the outcome [56]. 
On the other hand, the most important benefit of PCI in chronic stable CAD may be the 
relief of symptoms [57]. Statin therapy is effective for chronic stable CAD [58]. 
Women experience more bleeding than men with antiplatelet therapy and/or anticoagulant 
therapy as they often have a smaller body size, resulting in excessive dosing. These agents 
should be used with regard to the patient’s body size [59]. In a primary prevention trial in 
women, aspirin lowered the risk of stroke without affecting the risk of MI. On the other 
hand, in men, aspirin lowered the risk of MI without affecting the risk of stroke [60,61]. 
Angiotensin-converting enzyme inhibitors, angiotensin receptor blockers and warfarin for 
blood pressure control are contraindicated in women contemplating pregnancy and in those 
who are pregnant. 
The perception of the risks and benefits of hormone replacement therapy (HRT) and the 
time when the therapy should be initiated has changed dramatically since the publication of 
the Women’s Health Initiative trial in 2002. This study of women in whom HRT was 
initiated on average 13 years after menopause did not reveal long-term benefits for 
cardiovascular outcomes [62]. However, combined HRT started many years after 
menopause can improve health-related quality of life [63]. 
Reports show 20% reduction in total mortality among patients randomized to exercise-based 
cardiac rehabilitation compared with controls receiving usual care. The outcome is similar 
between men and women, although only 20% of all participants were women in many 
reports. Women are less likely than men to participate in cardiac rehabilitation after acute 
MI [11]. This may be one reason for the poor outcome in women with AMI. Cardiac 
rehabilitation should be recommended to more women after AMI. 
7. Conclusions 
Appropriate diagnosis, prevention, and treatment will improve the care of all CAD patients. 
Since there are gender differences in ischemic heart disease, it is necessary to consider these 
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differences when examining men and women with ischemic heart disease. We have found 
many gender differences in CAD. The development of novel drugs and therapeutic methods 
for tailor-made therapy of CAD based on gender differences is required. 
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